Sammy Farah, Turnstone Biologics CEO

Take­da ax­es clin­i­cal-stage pro­gram in $1B+ Turn­stone Bi­o­log­ics col­lab­o­ra­tion

Take­da has end­ed its work with Turn­stone Bi­o­log­ics on a sol­id tu­mor as­set that was in a Phase I/IIa study, up­end­ing a 2019 deal that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.